Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Calliditas announces poster presentations at ASN Digital Kidney Week 2021

Calliditas announces acquisition of remaining Genkyotex minority shares

Calliditas Receives FDA Fast Track Designation for setanaxib in PBC

Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference

Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021

Calliditas promotes Andrew Udell to President, North America

Calliditas strengthens its US Commercial and Medical Affairs Organization

Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice

First Patient Dosed in NefIgArd Open Label Extension Study

Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial

Positive Phase 1 results in high-dose setanaxib trial

Agenda for Calliditas virtual R&D Day on January 20, 2021

Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex

Calliditas wins the 2020 SwedenBio Award

Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021

Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report

Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial

Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020

The 200[th] patient’s last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020

First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon

Calliditas appoints Group General Counsel

Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report

CEO Renée Aguiar-Lucander exercises warrants and invests SEK 15.7m (appr. USD 1.7m) in Calliditas

Calliditas provides a corporate business update in the context of the Covid-19 pandemic

Calliditas strengthens its US Commercial Organization

Positive opinion received from EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the treatment of IgAN

The pivotal Phase 3 clinical trial NefIgArd Part A fully recruited

Calliditas Therapeutics Capital Markets Day today November 4

Save the date: Calliditas to host Capital Markets Day in Stockholm on November 4, 2019

Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q2 report

Calliditas Therapeutics to Present at Redeye Growth Day

Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q1 report

Elmar Schnee and Diane Parks proposed as new board members of Calliditas Therapeutics

Calliditas Therapeutics to Present at the Needham Healthcare Conference

Calliditas Therapeutics to Present at March Investor Conferences

Calliditas Therapeutics to host conference call to provide Business Update and 2018 full-year report

Calliditas Therapeutics appoints Frank Bringstrup as VP Regulatory Affairs

Calliditas Therapeutics appoints Andrew Udell to VP Commercial, North America

Calliditas Therapeutics to present and attend investor conferences in November 2018

Calliditas Therapeutics to host conference call to provide Q3 2018 Business Update

Presentation at International IgA Nephropathy Network meeting highlighting supportive post-hoc analysis of the NEFIGAN study

Post-hoc results from NEFIGAN study to be presented at the International IgA Nephropathy Network meeting (IIgANN)

Calliditas Therapeutics to host conference call to provide Q2 2018 Business Update

The 15th International Symposium on IgA nephropathy accepts Calliditas Therapeutics abstracts

Calliditas Therapeutics selected to present at the 25th Annual NewsMakers in the Biotech Industry

Trading in Calliditas’ share commences today on Nasdaq Stockholm

Pharmalink enters manufacturing agreement for Nefecon®